What AbbVie's 8-K filings say: 12 filings, latest Nov 2, 2026
AbbVie filed its latest 8-K with the SEC on Nov 2, 2026. It discusses board change.
Public (ABBV)Pharmaceutical Manufacturing10,000+ employeesabbvie.comLinkedIn
Get AbbVie's live signals in Claude or ChatGPT, or by API
What changed at AbbVie this week? Use Autobound signals for abbvie.com.- Filed
- Nov 2, 2026
- Filings
- 12
- Signals
- 29
Source: Autobound Signal API · 110 signals tracked for AbbVie · updated
8-K · latest 10
What AbbVie's 8-K filings say
- SEC EDGAR
8-K
Filed · 1 signal
Class II Director Jennifer L. Davis Resigns from AbbVie Board Effective November 2, 2026
Jennifer L. Davis notified AbbVie of her intent to resign as a Class II director effective November 2, 2026, following her appointment as CEO of Align Technology.
- SEC EDGAR
8-K
Filed · 1 signal
AbbVie completes acquisition of Apogee Therapeutics, deepening immunology pipeline
AbbVie announced it completed its acquisition of Apogee Therapeutics, adding assets including zumilokibart and APG273 to its immunology pipeline.
- SEC EDGAR
8-K
Filed · 1 signal
AbbVie Expands Board to 13 Members and Appoints Dr. John M. Carethers
Dr. John M. Carethers, Vice Chancellor for Health Sciences at UC San Diego, joins the Board and the Public Policy and Sustainability Committee.
- SEC EDGAR
8-K
Filed · 2 signals
AbbVie discloses $216M expense for acquired R&D and asset acquisitions in Q3 2026
AbbVie has incurred a $216 million expense for acquired In-Process Research & Development (IPR&D) and milestones, indicating recent, significant investment in external innovation through acquisitions or licensing.
$216M
Acquired IPR&D and milestones expense on a pre-tax basis for the third quarter of 2026.
AbbVie reports $216M R&D expense, reducing Q3 2026 earnings guidance
The company incurred a $216 million expense for acquired In-Process Research and Development (IPR&D), creating an unfavorable impact of $0.11 per share.
$216M
Acquired IPR&D and milestones expense
- SEC EDGAR
8-K
Filed · 3 signals
AbbVie completes acquisition of Apogee Therapeutics, Inc.
The completion of this acquisition triggers significant post-merger integration (PMI) activities.
- SEC EDGAR
8-K
Filed · 3 signals
AbbVie has secured $10 billion in financing for its acquisition of Apogee Therapeutics.
$10B
Total capital raised from a public notes offering to fund the acquisition of Apogee Therapeutics, Inc. and related fees.
U.S. Bank Trust Company, National AssociationWachtell, Lipton, Rosen & Katz
- SEC EDGAR
8-K
Filed · 3 signals
AbbVie raises $9.93B in debt to fund acquisition of Apogee Therapeutics
AbbVie is raising nearly $10 billion in net proceeds from a senior notes offering specifically to finance its acquisition of Apogee Therapeutics.
$9.9B
Net proceeds from debt offering to fund the acquisition of Apogee Therapeutics, Inc.
Morgan Stanley & Co. LLCBofA Securities, Inc.J.P. Morgan Securities LLCSG Americas Securities, LLC
- SEC EDGAR
8-K
Filed · 3 signals
AbbVie invests $291M in acquired R&D and milestones in Q2 2026
AbbVie is spending $291 million on collaborations, licensing, and asset acquisitions to strengthen its R&D pipeline.
$291M
Acquired IPR&D and milestones expense for Q2 2026
AbbVie signals recent acquisition or licensing deal with $291M R&D expense in Q2 2026
AbbVie incurred a $291 million expense for acquired In-Process Research & Development (IPR&D), indicating a recent asset acquisition, collaboration, or licensing agreement.
$291M
acquired IPR&D and milestones expense
Showing 10 of 29 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track AbbVie with the Signal API
One POST /v1/companies/enrich call with abbvie.com returns AbbVie 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","signal_types":["sec-8k"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 8-K Filings records, as a CSV.
Same industry
8-K at related companies
Questions about AbbVie 8-K
When did AbbVie file its latest 8-K?
What did AbbVie disclose in its latest 8-K?
Where can I read AbbVie's 8-K filing?
Page updated , the date of the newest row on this page.
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .